|
|
|
|
|
|
Sponsors and Collaborators: |
Accelerated Community Oncology Research Network GlaxoSmithKline Genentech |
Information provided by: | Accelerated Community Oncology Research Network |
ClinicalTrials.gov Identifier: | NCT00611468 |
The purpose of this research study is to determine the best dose of the combination of two approved drugs, intravenous (into a vein, IV) topotecan and oral (by mouth) erlotinib.
Condition | Intervention | Phase |
Metastatic Solid Tumor |
Drug: Topotecan Drug: Erlotinib |
Phase I |
MedlinePlus related topics: | Cancer |
ChemIDplus related topics: | Topotecan hydrochloride Topotecan Erlotinib Erlotinib hydrochloride |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Single Group Assignment, Safety Study |
Official Title: | A Phase I, Dosage-Finding and Pharmacokinetic Study of Intravenous Topotecan and Oral Erlotinib in Adults With Refractory Solid Tumors |
Estimated Enrollment: | 24 |
Study Start Date: | June 2006 |
Estimated Study Completion Date: | May 2009 |
Estimated Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
1: Experimental
A "traditional cohorts of 3" dosage escalation scheme will be followed for topotecan therapy. Here, 3 patients will be assigned to the starting dosage (cohort 1). The number of patients that reach a DLT will be assessed. Interim analysis has determined 1.0 mg intravenous topotecan + 150 mg erlotinib as MTD. 6 additional patients will be enrolled at MTD of 1.0 mg of topotecan + erlotinib to determine tolerability and safety of multiple cycles at MTD. After additional analyses, the decision has been made to add an additional 6 patients at the 0.75 mg/m2 dose of intravenous topotecan + 150 mg erlotinib because the PK interaction between topotecan and erlotinib has not been clearly established.
|
Drug: Topotecan
A "traditional cohorts of 3" dosage escalation scheme will be followed for topotecan therapy. Here, 3 patients will be assigned to the starting dosage (cohort 1). The number of patients that reach a DLT will be assessed. Interim analysis has determined 1.0 mg intravenous topotecan + 150 mg erlotinib as MTD. 6 additional patients will be enrolled at MTD of 1.0 mg of topotecan + erlotinib to determine tolerability and safety of multiple cycles at MTD.
Drug: Erlotinib
A "traditional cohorts of 3" dosage escalation scheme will be followed for topotecan therapy. Here, 3 patients will be assigned to the starting dosage (cohort 1). The number of patients that reach a DLT will be assessed. Interim analysis has determined 1.0 mg intravenous topotecan + 150 mg erlotinib as MTD. 6 additional patients will be enrolled at MTD of 1.0 mg of topotecan + erlotinib to determine tolerability and safety of multiple cycles at MTD.
|
The primary objectives of this trial include:
The secondary objectives include:
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Amanda Johns, RHIA, CCRP | 901-435-5570 ext 1527 | ajohns@sosacorn.com |
Contact: Cindy Lee, RN, MSN,CCRP | 901-435-5570 ext 1736 | clee@sosacorn.com |
United States, Tennessee | |||||
The West Clinic | Recruiting | ||||
Memphis, Tennessee, United States, 38120 | |||||
Principal Investigator: Lee S. Schwartzberg, MD, FACP |
Accelerated Community Oncology Research Network |
GlaxoSmithKline |
Genentech |
Principal Investigator: | Lee S. Schwartzberg, MD, FACP | Accelerared Community Oncology Research Network, Inc. |
Responsible Party: | Accelerated Community Oncology Research Network ( Amanda Johns, RHIA, CCRP ) |
Study ID Numbers: | ACORN ALSSRST0501 |
First Received: | January 29, 2008 |
Last Updated: | August 28, 2008 |
ClinicalTrials.gov Identifier: | NCT00611468 |
Health Authority: | United States: Institutional Review Board |
|
|
|